Nephrotic Syndrome: Diagnosis to Management
Definition and Diagnostic Criteria
Nephrotic syndrome is diagnosed when you have nephrotic-range proteinuria (uPCR ≥200 mg/mmol or ≥2 g/g) plus either hypoalbuminemia (serum albumin <30 g/L) or edema when albumin is unavailable 1, 2.
Key Diagnostic Features:
- Proteinuria: uPCR ≥200 mg/mmol (2 g/g) in spot urine, or ≥1000 mg/m² per day in 24-hour collection (dipstick 3+ or 4+)
- Hypoalbuminemia: Serum albumin <30 g/L (3 g/dL)
- Edema: Periorbital (morning) or dependent pitting edema (later in day) 3
- Hyperlipidemia: Commonly present but not required for diagnosis
Response Definitions You Must Know:
Complete remission: uPCR ≤200 mg/g (negative/trace dipstick) on 3+ consecutive days 2
Partial remission: uPCR >200 mg/g but <2 g/g with serum albumin ≥30 g/L 2
Relapse: Recurrence of nephrotic-range proteinuria (dipstick ≥3+ for 3 consecutive days) after achieving complete remission 2
Initial Diagnostic Workup
Confirm the Diagnosis:
- Quantify proteinuria: Use urine PCR or ACR (PCR >300-350 mg/mmol indicates nephrotic range) 3
- Measure serum albumin and lipid panel
- Check renal function: Serum creatinine, eGFR
Search for Secondary Causes:
- Blood glucose/HbA1c: Diabetic nephropathy (most common systemic cause) 3
- Autoimmune workup: ANA, complement levels, anti-dsDNA for SLE
- Infection screen: Hepatitis B/C, HIV
- Malignancy screen: Age-appropriate cancer screening, serum/urine protein electrophoresis
- Medication review: NSAIDs, gold, penicillamine, lithium 4
Age-Specific Etiologies:
Children (1-18 years): Minimal change disease most common (80-90% steroid-sensitive) 5, 6
White adults: Membranous nephropathy most common 3
African ancestry populations: Focal segmental glomerulosclerosis (FSGS) most common 3
Biopsy Decision Algorithm
Children:
Do NOT biopsy initially if age 1-12 years with typical presentation 5. Start glucocorticoids first.
- Biopsy indicated if: Age <1 year, age >12 years, atypical features (hematuria, hypertension, low complement, elevated creatinine), steroid resistance after 4 weeks, or genetic testing concerns 5, 6
Adults:
Biopsy is typically required before treatment 7, with one critical exception:
- Skip biopsy if: Positive serum anti-phospholipase A2 receptor (PLA2R) antibodies—this is diagnostic of membranous nephropathy 5
Initial Treatment: Children
First Episode (Steroid-Sensitive NS):
Give oral prednisone/prednisolone for either 8 weeks (4 weeks daily + 4 weeks alternate-day) OR 12 weeks (6 weeks daily + 6 weeks alternate-day) 1. Both regimens are equally effective (1B evidence).
Steroid-sensitive NS (SSNS): Complete remission within 4 weeks of standard-dose prednisone/prednisolone 2
Relapse Classification System:
Infrequently relapsing: <2 relapses in first 6 months OR <3 relapses in any 12-month period 2
Frequently relapsing: ≥2 relapses in first 6 months OR ≥3 relapses per 12 months 2
Steroid-dependent: 2 consecutive relapses during therapy (full-dose or tapering) OR within 14 days of discontinuation 2
Managing Relapses:
For infrequent relapses: Use the same glucocorticoid regimen as initial episode 1
For children with glucocorticoid toxicity: Use shorter taper and consider steroid-sparing agents earlier 1
Infection-Associated Relapses—Critical Update:
Do NOT routinely give daily glucocorticoids during upper respiratory infections to prevent relapses 1. The PREDNOS2 study showed no benefit (1C recommendation).
Exception: Consider 3 extra doses of low-dose prednisone (0.5 mg/kg/day) at URI onset ONLY if the child is already on alternate-day prednisolone AND has history of repeated infection-associated relapses with significant steroid-related morbidity 1.
Steroid-Sparing Agents
When to Use:
Initiate glucocorticoid-sparing agents for:
- Frequently relapsing NS with serious glucocorticoid adverse effects (1B recommendation) 1
- ALL children with steroid-dependent NS (1B recommendation) 1
For frequently relapsing NS without glucocorticoid toxicity: Low-dose alternate-day prednisone/prednisolone may be continued before introducing steroid-sparing agents 1
Agent Selection—No Longer First-Line vs. Alternative:
The 2025 KDIGO guideline eliminated the hierarchy of first-line versus alternative agents 1. Instead, choose based on relapse pattern:
For frequently relapsing NS (prefer):
- Oral cyclophosphamide
- Levamisole
For steroid-dependent NS (prefer):
- Mycophenolate mofetil
- Rituximab (1-4 doses, insufficient data for specific dosing recommendation)
- Calcineurin inhibitors (tacrolimus, cyclosporine)
- Oral cyclophosphamide (to lesser extent)
How to Initiate:
- Patient should be in remission with glucocorticoids before starting steroid-sparing agent 1
- Continue glucocorticoids for 2 weeks after initiating the steroid-sparing agent 1
Steroid-Resistant Nephrotic Syndrome (SRNS)
SRNS definition: Lack of complete remission within 4 weeks of daily prednisone/prednisolone at standard dose 2
Mandatory Next Steps:
- Genetic testing: Essential to identify monogenic causes 5, 6
- Kidney biopsy: Required to determine histological diagnosis 5, 6
Treatment Challenges:
SRNS management remains difficult with limited options 6. Multidrug-resistant SRNS carries high risk of progression to end-stage kidney disease 6. Consider:
- CNIs (tacrolimus/cyclosporine)
- B-cell-directed therapies
- Referral to specialized center
Supportive Management (All Patients)
Edema Control:
- Dietary sodium restriction: <2 g/day
- Loop diuretics: Furosemide as primary agent 8
- Monitor for intravascular volume depletion
Antiproteinuric Therapy:
- ACE inhibitors or ARBs: Reduce proteinuria and slow progression
- Target blood pressure control
Lipid Management:
- Statins: For hyperlipidemia 8
Thromboembolism Prophylaxis:
Consider anticoagulation for high-risk patients, particularly membranous nephropathy 5. Risk factors include:
- Severe hypoalbuminemia (<20 g/L)
- Prolonged immobility
- Membranous nephropathy specifically
Infection Prevention:
- Pneumococcal vaccination
- Monitor for peritonitis, cellulitis, sepsis (increased risk due to immunoglobulin loss and immunosuppression)
Long-Term Monitoring
Home Monitoring:
Train patients/families to check urine dipstick at home 6. This enables early relapse detection (3+ protein on 3 consecutive days).
Clinic Follow-Up:
- Frequent monitoring during active disease: Weekly to biweekly
- Stable remission: Every 3-6 months
- Monitor for:
- Proteinuria (uPCR)
- Renal function (creatinine, eGFR)
- Medication adverse effects
- Growth parameters (children)
- Blood pressure
Prognosis
Steroid-sensitive NS: Excellent long-term kidney outcomes 6. Many children continue relapsing into adulthood but maintain kidney function.
Steroid-resistant NS: High risk of progression to ESKD, especially if multidrug-resistant 6. Requires subspecialist co-management.
Critical Pitfalls to Avoid
- Do not biopsy children 1-12 years with typical presentation before steroid trial 5
- Do not give prophylactic steroids for every URI—PREDNOS2 showed no benefit 1
- Do not continue glucocorticoids alone in steroid-dependent NS—always add steroid-sparing agent 1
- Do not delay genetic testing in SRNS—changes management fundamentally 6
- Do not forget thromboembolism prophylaxis in membranous nephropathy 5
- Do not assume adult NS is minimal change disease—biopsy required (except PLA2R+ membranous) 7